Press Releases

Date Title and Summary Additional Formats
Toggle Summary RusnanoMedInvest and Domain Associates Invest In Neurology Company Marinus Pharmaceuticals
RusnanoMedInvest and Domain Associates Invest In Neurology Company Marinus Pharmaceuticals BRANFORD, Conn. , Jan. 7, 2013 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano...
View HTML
Toggle Summary Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome NEW HAVEN, Conn. , April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the...
View HTML
Toggle Summary Marinus Pharmaceuticals Issued Patent for Ganaxolone
Marinus Pharmaceuticals Issued Patent for Ganaxolone NEW HAVEN, Conn. , April 7, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the...
View HTML
Toggle Summary Marinus Pharmaceuticals Raises $20 Million in Series B Financing
Company to Advance Ganaxolone Program for the Treatment of Epilepsy...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures BRANFORD, Conn. , March 3 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. today announced that it met its primary endpoint for its Phase 2...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc., Completes Two Phase 2 Milestones for Ganaxolone in Epilepsy.
Marinus Closes Phase 2 Trials for Infantile Spasms and Completes Enrollment for Phase 2 Trial in Adult Partial Complex Seizures...
View HTML
Toggle Summary Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Adult Partial Seizures
Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Adult Partial Seizures BRANFORD, Conn., May 4 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on novel drugs to treat serious neurological disorders, today announced that it is enrolling...
View HTML
Toggle Summary Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Infantile Spasms
Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Infantile Spasms BRANFORD, Conn., Feb. 28 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on novel drugs to treat serious neurological disorders, today announced the dosing of the first...
View HTML
Toggle Summary Marinus Pharmaceuticals Raises $29.4 Million in Series A Financing.
Marinus Pharmaceuticals Raises $29.4 Million in Series A Financing. BRANFORD, Conn., Oct. 25 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a new developer of drugs to treat serious central nervous system disorders, today announced the closing of a $29.4 million Series A financing round....
View HTML